School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea.
J Pharm Sci. 2012 Mar;101(3):1314-26. doi: 10.1002/jps.23007. Epub 2011 Dec 6.
Bax inhibitor-1 (BI-1) is an evolutionarily conserved cell death suppressor in both animals and plants. We examined the effect of doxorubicin (DXR) and daunorubicin (DNR), which are clinically important anthracycline compounds, on the functional regulation of BI-1 reconstituted into membranes. DXR and DNR inhibited the proton-induced efflux of encapsulated Ca(2+) from membranes in a drug concentration-dependent manner. Both compounds also reduced the H(+) influx activity of BI-1. The proteoliposomes containing BI-1 increased the quenching of DXR fluorescence by Cu(2+), and the fluorescence energy transfer between pyrene-labeled BI-1 and DXR was enhanced with increasing DXR concentrations. The dissociation constants and the number of binding sites for both drugs in BI-1 were determined to be in the range of 3.7-4.5 × 10(-6) m and approximately 4-5/BI-1 molecule, respectively, using a proteomicelle system. DXR also induced secondary structural changes in reconstituted BI-1 and abolished the ability of BI-1-overexpressing cells to protect against endoplasmic reticulum stress-induced cell death. However, when mitoxantrone was used instead of DNR and DXR as an anthracycline analog, no significant effects were observed. These results suggest that BI-1 can be considered to be a new cancer therapeutic target by anthracyclines because of its stimulatory effects in cancer/tumor progression.
Bax 抑制剂-1(BI-1)是一种在动物和植物中都具有进化保守性的细胞死亡抑制剂。我们研究了多柔比星(DXR)和柔红霉素(DNR)这两种临床上重要的蒽环类化合物对重新构建到膜中的 BI-1 的功能调节的影响。DXR 和 DNR 以药物浓度依赖的方式抑制了包裹在膜中的 Ca(2+)在质子诱导下的流出。这两种化合物还降低了 BI-1 的 H(+)内流活性。含有 BI-1 的脂质体增加了 DXR 荧光被 Cu(2+)猝灭的程度,并且随着 DXR 浓度的增加,芘标记的 BI-1 和 DXR 之间的荧光能量转移增强。使用蛋白质胶束系统,确定了这两种药物与 BI-1 的解离常数和结合位点数量分别在 3.7-4.5×10(-6) m 和大约 4-5/BI-1 分子的范围内。DXR 还诱导了重新构建的 BI-1 的二级结构变化,并使过表达 BI-1 的细胞丧失了抵抗内质网应激诱导的细胞死亡的能力。然而,当米托蒽醌代替 DNR 和 DXR 作为蒽环类抗生素类似物时,没有观察到明显的效果。这些结果表明,由于 BI-1 对癌症/肿瘤进展具有刺激作用,因此可以将其视为蒽环类药物的新的癌症治疗靶标。